logoTry Persana

Cytokinetics - Company Overview, Founder, CEO, Funding & Investment Details

Complete information about Cytokinetics including founder details, CEO information, total funding raised, headquarters location, team size, and recent investment rounds.

Cytokinetics company logo

Empowering Muscle Empowering Lives

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases related to muscle performance.

HeadquartersSouth San Francisco, United States
Team size500-1000
Founded1998

What is Cytokinetics? - Company Overview & Details

Cytokinetics is Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases related to muscle performance. Founded in 1998, the company is headquartered in South San Francisco, United States.

Who are the Key Executives at Cytokinetics? - Leadership Team

Cytokinetics is led by experienced executives in key positions:

Cytokinetics Company Details & Key Information

Where is Cytokinetics located?

Cytokinetics is headquartered in South San Francisco, United States.

How many employees does Cytokinetics have?

Cytokinetics has 500-1000 employees.

When was Cytokinetics founded?

Cytokinetics was founded in 1998.

How much funding has Cytokinetics raised?

Cytokinetics has raised $1 Billion across 11 funding rounds. The most recent funding was completed on 2024-06-22.

Funding Overview

Cytokinetics has successfully raised substantial funding to support its development of innovative therapies aimed at enhancing muscle performance in patients.

$1 Billion
Total Funding Raised
11
Funding Rounds
2024-06-22
Latest Round

Cytokinetics Funding History

Post IPO debt
2022-08-01
$450 Million
Post IPO equity
2024-06-22
$550 Million

Who are the key investors in Cytokinetics?

Cytokinetics is backed by 1 key investors including Royalty Pharma. These investors focus on biopharmaceuticals, muscle biology sectors.

Cytokinetics Investor Overview

1
Key Investors
2
Focus Areas
1
Notable Investments

Complete List of Cytokinetics Investors

Royalty Pharma

A leading investment firm in the pharmaceutical sector.

Investment Focus
biopharmaceuticals
muscle biology
Notable Portfolio Companies
Cytokinetics

What sectors do Cytokinetics investors focus on?

The investors backing Cytokinetics primarily focus on biopharmaceuticals, muscle biology sectors.

biopharmaceuticals
muscle biology

Featured Investor: Royalty Pharma

Royalty Pharma

A leading investment firm in the pharmaceutical sector.

Notable Investments: Cytokinetics

What are Cytokinetics's future plans?

Cytokinetics Cytokinetics plans to launch aficamten, a cardiac myosin inhibitor, while continuing to develop other muscle-related therapies.

Cytokinetics Strategic Outlook

Strategic Focus
Defined
2
Key Challenges
2
Growth Opportunities

What challenges does Cytokinetics face?

Cytokinetics has identified 2 key challenges that need to be addressed for continued growth and success.

Key Challenges for Cytokinetics

1

Regulatory hurdles

2

Market competition

What opportunities does Cytokinetics have?

Cytokinetics has identified 2 key opportunities for growth and market expansion.

Growth Opportunities for Cytokinetics

1

Expand into international markets

2

Leverage partnerships for growth

Cytokinetics Strategic Position Summary

Key Focus Areas

Cytokinetics is addressing 2 strategic challenges to strengthen its market position.

Growth Potential

The company has identified 2 key opportunities for expansion and growth.

What are the latest news about Cytokinetics?

Cytokinetics has 2 recent news updates covering key business developments and market activities.

Cytokinetics News Overview

2
Recent Articles
Active
Media Coverage
2025-05-15
Latest Update

What is Cytokinetics in the news for?

Cytokinetics is currently featured in news for Cytokinetics attended event Contemporary Landscapes in Muscle Biology Research Symposium on May 30th '25. and other significant business developments.

Recent News Articles About Cytokinetics

Article 1
2025-05-15

Cytokinetics attended event Contemporary Landscapes in Muscle Biology Research Symposium on May 30th '25.

Cytokinetics to host symposium on Contemporary Landscapes in Muscle Biology, highlighting innovations in the field.

stocktitan.net
Read News
Article 2
2025-03-20

Cytokinetics unveils EARTH-HCM, an interactive online tool aimed at enhancing the understanding and management of HCM.

Cytokinetics launches EARTH-HCM to provide insights into HCM treatment patterns and patient characteristics.

investing.com
Read News

Cytokinetics FAQ - Frequently Asked Questions About Founder, CEO, Funding & Company Details

Find answers to the most common questions about Cytokinetics including information about founders, CEO, funding history, investors, headquarters location, and company details. 14 frequently asked questions covering key information about the company.

Cytokinetics Questions & Answers - Company Information

Q1

What is Cytokinetics?

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases related to muscle performance.

Q2

How much funding has Cytokinetics raised?

Cytokinetics has raised a total of $$1 Billion across 11 funding rounds. The most recent funding was completed on 2024-06-22.

Q3

Who are the investors in Cytokinetics?

Cytokinetics's key investors include Royalty Pharma.

Q4

Where is Cytokinetics headquartered?

Cytokinetics is headquartered in South San Francisco, United States.

Q5

When was Cytokinetics founded?

Cytokinetics was founded in 1998.

Q6

How many employees does Cytokinetics have?

Cytokinetics has 500-1000 employees.

Q7

What was Cytokinetics's latest funding round?

Cytokinetics's latest funding round was a Post IPO debt round of $$450 Million completed on 2022-08-01.

Q8

What does the company do?

Cytokinetics develops innovative therapeutics aimed at improving muscle function for various diseases.

Q9

How much funding?

$1 Billion

Q10

Latest funding date?

2024-06-22

Q11

Who are the investors?

Royalty Pharma

Q12

What are the challenges?

Regulatory hurdles Market competition

Q13

What are the opportunities?

Expand into international markets Leverage partnerships for growth

Q14

Latest news?

Cytokinetics to host symposium on Contemporary Landscapes in Muscle Biology, highlighting innovations in the field. Cytokinetics launches EARTH-HCM to provide insights into HCM treatment patterns and patient characteristics.

More Information About Cytokinetics

For additional details about Cytokinetics, including the latest news, funding updates, and company developments, explore our comprehensive company database. Find information about startup funding, company valuations, executive leadership, and business intelligence data.